Table S1.
Direct meta-analysis of American College of Rheumatology (ACR) criteria scores of 20, 50, and 70 outcomes: combination therapy
| Treatment | Fixed effect | Random effects | ||
|---|---|---|---|---|
|
|
|
|||
| OR v DMARD (95% CI) | P-value | OR v DMARD (95% CI) | P-value | |
| ACR 20 | ||||
| ABA 10 mg/kg/4 weeks + DMARD | 2.996 (2.338, 3.839) | <0.001 | 2.997 (2.339, 3.841) | <0.001 |
| ADA 40 mg/2 weeks + DMARD | 3.433 (2.589, 4.552) | <0.001 | 3.332 (1.667, 6.661) | 0.001 |
| CZP 200 mg/2 weeks + DMARD | 10.583 (7.284, 15.377) | <0.001 | 10.57 (6.991, 15.983) | <0.001 |
| ETN 2 × 25 mg/week + DMARD | 8.198 (4.724, 14.224) | <0.001 | 8.092 (4.645, 14.095) | <0.001 |
| GOL 50 mg/4 weeks + DMARD | 3.432 (2.105, 5.596) | <0.001 | 3.437 (2.107, 5.608) | <0.001 |
| INF 3 mg/kg/8 weeks + DMARD | 3.406 (2.726, 4.257) | <0.001 | 3.359 (2.488, 4.536) | <0.001 |
| RTX 2 × 1000 mg + DMARD | 3.553 (2.345, 5.384) | <0.001 | 3.554 (2.345, 5.387) | <0.001 |
| TOC 8 mg/kg/4 weeks + DMARD | 4.48 (3.595, 5.582) | <0.001 | 4.472 (3.589, 5.572) | <0.001 |
| ACR 50 | ||||
| ABA 10 mg/kg/4 weeks + DMARD | 3.281 (2.444, 4.406) | <0.001 | 3.278 (2.441, 4.403) | <0.001 |
| ADA 40 mg/2 weeks + DMARD | 3.622 (2.62, 5.007) | <0.001 | 3.881 (1.407, 10.702) | 0.009 |
| CZP 200 mg/2 weeks + DMARD | 8.927 (5.453, 14.614) | <0.001 | 9.077 (4.706, 17.51) | <0.001 |
| ETN 2 × 25 mg/week + DMARD | 9.779 (4.822, 19.832) | <0.001 | 9.409 (4.635, 19.102) | <0.001 |
| GOL 50 mg/4 weeks + DMARD | 4.493 (2.468, 8.18) | <0.001 | 4.577 (2.145, 9.764) | <0.001 |
| INF 3 mg/kg/8 weeks + DMARD | 3.525 (2.671, 4.652) | <0.001 | 3.455 (2.295, 5.202) | <0.001 |
| RTX 2 × 1000 mg + DMARD | 3.791 (2.208, 6.509) | <0.001 | 3.792 (2.207, 6.513) | <0.001 |
| TOC 8 mg/kg/4 weeks + DMARD | 5.841 (4.373, 7.802) | <0.001 | 5.57 (3.844, 8.069) | <0.001 |
| ACR 70 | ||||
| ABA 10 mg/kg/4 weeks + DMARD | 3.76 (2.42, 5.83) | <0.001 | 3.77 (2.05, 6.93) | <0.001 |
| ADA 40 mg/2 weeks + DMARD | 3.66 (2.32, 5.79) | <0.001 | 3.78 (1.28, 11.15) | 0.016 |
| CZP 200 mg/2 weeks + DMARD | 11 (5.06, 23.94) | <0.001 | 10.18 (4.67, 22.22) | <0.001 |
| ETN 2 × 25 mg/week + DMARD | 15.58 (3.67, 66.2) | <0.001 | 15.64 (3.7, 66.18) | <0.001 |
| GOL 50 mg/4 weeks + DMARD | 4.85 (2.01, 11.67) | <0.001 | 4.77 (1.98, 11.5) | <0.001 |
| INF 3 mg/kg/8 weeks + DMARD | 3.18 (2.17, 4.66) | <0.001 | 3 (2.03, 4.44) | <0.001 |
| RTX 2 × 1000 mg + DMARD | 2.33 (1.11, 4.88) | 0.025 | 2.52 (0.87, 7.31) | 0.089 |
| TOC 8 mg/kg/4 weeks + DMARD | 8.13 (5.13, 12.88) | <0.001 | 7.27 (3.33, 15.89) | <0.001 |
Note:P < 0.05 is statistically significant.
Abbreviations: ABA, abatacept; ADA, adalimumab; ANA, anakinra; CI, confidence interval; CZP, certolizumab pegol; DMARD, disease-modifying antirheumatic drug (MTX or SUL); ETN, etanercept; exp, experienced; GOL, golimumab; INF, infliximab; MTX, methotrexate; OR, odds ratio; RTX, rituximab; SUL, sulfasalazine; TOC, tocilizumab.